Literature DB >> 10878580

Role of erbB2 in breast cancer chemosensitivity.

D Yu1, M C Hung.   

Abstract

The erbB2 gene, which encodes a transmembrane growth factor receptor, is overexpressed in approximately 30% of breast cancers. Overexpressing this gene makes breast cancers resistant to certain chemotherapeutic agents. In this article, we review what is known about ErbB2-mediated chemoresistance and the controversies surrounding it. We also examine the antiapoptotic function of erbB2 as one of the molecular mechanisms of ErbB2-mediated Taxol resistance and describe several emerging strategies for overcoming intrinsic ErbB2-mediated chemoresistance. Finally, we discuss future avenues for studies of chemosensitivity in ErbB2-overexpressing breast cancers that may lead to the development of effective biology-based treatment strategies.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10878580     DOI： 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A

Source DB:  PubMed          Journal:  Bioessays        ISSN： 0265-9247            Impact factor:   4.345


  24 in total

Review 1.  Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells.

Authors:  S Bafna; S Kaur; S K Batra
Journal:  Oncogene       Date:  2010-03-29       Impact factor: 9.867

Review 2.  The ErbB2 signaling network as a target for breast cancer therapy.

Authors:  Ali Badache; Anthony Gonçalves
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

3.  ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.

Authors:  Valerie S Hawthorne; Wen-Chien Huang; Christopher L Neal; Ling-Min Tseng; Mien-Chie Hung; Dihua Yu
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

4.  Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.

Authors:  Qingqing Ding; Longfei Huo; Jer-Yen Yang; Weiya Xia; Yongkun Wei; Yong Liao; Chun-Ju Chang; Yan Yang; Chien-Chen Lai; Dung-Fang Lee; Chia-Jui Yen; Yun-Ju Rita Chen; Jung-Mao Hsu; Hsu-Ping Kuo; Chun-Yi Lin; Fuu-Jen Tsai; Long-Yuan Li; Chang-Hai Tsai; Mien-Chie Hung
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

5.  Inhibition of the HER2 pathway by n-3 polyunsaturated fatty acids prevents breast cancer in fat-1 transgenic mice.

Authors:  Zuquan Zou; Sandrine Bellenger; Karen A Massey; Anna Nicolaou; Audrey Geissler; Célia Bidu; Bernard Bonnotte; Anne-Sophie Pierre; Mélaine Minville-Walz; Michaël Rialland; John Seubert; Jing X Kang; Laurent Lagrost; Michel Narce; Jérôme Bellenger
Journal:  J Lipid Res       Date:  2013-09-19       Impact factor: 5.922

6.  Bioconjugated fluorescent polymeric nanoparticles for imaging and targeted therapy of HER2-overexpressing cancer cells.

Authors:  Tzong-Der Way; Chi-Jung Chang; Cheng-Wen Lin
Journal:  J Fluoresc       Date:  2011-03-01       Impact factor: 2.217

7.  Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis.

Authors:  Yong Liao; Mien-Chie Hung
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

8.  Increasing CD44+/CD24(-) tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.

Authors:  Kai-Hung Wang; An-Pei Kao; Chia-Cheng Chang; Jau-Nan Lee; Ming-Feng Hou; Cheng-Yu Long; Hung-Sheng Chen; Eing-Mei Tsai
Journal:  Mol Cancer       Date:  2010-11-02       Impact factor: 27.401

9.  The effect of hydrophilic substitutions and anionic lipids upon the transverse positioning of the transmembrane helix of the ErbB2 (neu) protein incorporated into model membrane vesicles.

Authors:  Khurshida Shahidullah; Shyam S Krishnakumar; Erwin London
Journal:  J Mol Biol       Date:  2009-11-18       Impact factor: 5.469

10.  The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.

Authors:  A B D'Assoro; T Liu; C Quatraro; A Amato; M Opyrchal; A Leontovich; Y Ikeda; S Ohmine; W Lingle; V Suman; J Ecsedy; I Iankov; A Di Leonardo; J Ayers-Inglers; A Degnim; D Billadeau; J McCubrey; J Ingle; J L Salisbury; E Galanis
Journal:  Oncogene       Date:  2013-01-21       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.